Pharmacologic Advancements in Obstructive Sleep Apnea: Recommendations for Managed Care
Jointly provided by
Impact Education, LLC    
This activity is supported by an independent educational grant from Jazz Pharmaceuticals, Inc.

You Are Invited to a LIVE Free CME/CNE/CPE Webcast:
Pharmacologic Advancements in Obstructive Sleep Apnea: Recommendations for Managed Care

Live Webcast Date

December 10, 2019 | 11:30am to 1:00pm ET

  • Characterize clinical and economic burden diagnosed and undiagnosed obstructive sleep apnea (OSA)
  • Outline available treatment modalities for OSA
  • Evaluate data on current and emerging pharmacotherapies
Jeffrey D. Dunn, PharmD, MBA
Vice President
Clinical Strategy and Programs and Industry Relations
MagellanRx Management
Edmund Pezalla, MD, MPH
Enlightenment Bioconsult, LLC
Phyllis C. Zee, MD, PhD
Director, Center for Circadian and Sleep Medicine
Professor of Neurology
Northwestern University Feinberg School of Medicine
  • Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
  • Pharmacy directors, specialty pharmacists, quality directors, care managers, registered nurses, and other managed care and payer organization professionals

Despite a sizeable associated disease burden, there is minimal knowledge among managed care professionals regarding the economic impact of OSA and potential cost offsets garnered through successful management. The complexity and high cost of OSA diagnosis (i.e., sleep studies and associated interventions) results in the majority of cases remaining undiagnosed, and low adherence to CPAP contributes to a lack of payer confidence in available treatment interventions. Even among those members who use CPAP optimally, excessive daytime sleepiness (EDS) often remains as a detrimental and life-altering effect. This educational activity is designed to address these pertinent needs and improve knowledge and competence among managed care professionals regarding OSA disease burden, the importance of timely and accurate diagnosis, and pharmacologic management of sequelae secondary to OSA.


After completing the activity, participants should be better able to:
  • Characterize the clinical and economic burden of both diagnosed and undiagnosed OSA as it pertains to comorbid conditions and EDS
  • Describe potential cost offsets garnered through appropriate therapeutic interventions for OSA
  • Apply available criteria, risk factors, and clinical indicators for the timely and accurate diagnosis of OSA
  • Cite available OSA screening methodology for dissemination and standardized use among network providers
  • Characterize the available treatment modalities for OSA in terms of outcomes and patient adherence
  • Evaluate the efficacy and safety data associated with available and emerging pharmacotherapies for the management of EDS in patients with OSA as they pertain to benefit design and coverage considerations
Opening Comments/Overview
Jeffrey D. Dunn, PharmD, MBA
Integrating Novel Therapies and Recent Evidence for OSA into Plan Algorithms and Management Strategies
Phyllis C. Zee, MD, PhD
Addressing Barriers for Appropriate OSA Therapy and Interventions for Optimal Member Access to Care
Jeffrey Dunn, PharmD, MBA
Multidisciplinary Collaborations for Successful Care with OSA Patients
Edmund Pezalla, MD, MPH
Faculty Idea Exchange
Audience Question and Answer Session

Key Takeaways and Closing Comments
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008162-9999-19-912-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

If you have any questions, please call (215) 619-8812 or email